Conditions: Breast Cancer Metastasis
Keywords: Recurrent, locally-advanced, or metastatic breast cancer
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 92
Healthy volunteers: no

Brief summary:
This study will determine whether the investigational drug dasatinib is effective in treatment of women with progressive advanced ER+/PR+ or Her2/neu+ breast cancer

Detailed description:

Arms:
arm 1: Participants with either a Human epidermal growth factor (Her2/neu)-amplified tumor type or ER and/or PgR positive tumor types received oral dasatinib twice daily (BID).

Interventions: intervention 1: Dasatinib intervention 2: Dasatinib 100 mg
Intervention descriptions: intervention 1: Tablets, Oral, 70 mg, twice daily, as long as the participant benefits (average \<6 months) intervention 2: Tablets, Oral, 100mg, twice daily, as long as the participant benefits (average \<6 months)

Protocol document: